NASDAQ:DERM
Journey Medical Corp
Journey Medical Corp's revenue grew 10.2% in fiscal 2025 to $61.9M while operating margin rose to −13.2%. The diluted share count rose 19.9%.Summary generated from Journey Medical Corp's SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$61.9M
Revenue growth+10.2%
Revenue, 5-yr CAGR+6.8%
Gross margin66.2%
Operating margin−13.2%
Net margin−18.5%
ROIC−22.4%
Return on equity−44.0%
Debt / equity0.79
Free cash flown/a
FCF marginn/a
Share count change+19.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 63 | 74 | 79 | 56 | 62 |
| Operating income | −35 | −28 | −2 | −14 | −8 |
| Net income | −44 | −30 | −4 | −15 | −11 |
| Free cash flow | n/a | −34 | 0 | −24 | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 4Insider transaction report
Jul 2, 2026 - 4Insider transaction report
Jul 2, 2026 - 8-KResults of a shareholder vote
Jun 26, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
May 13, 2026 - DEF 14AProxy statement
Apr 30, 2026